Cite
HARVARD Citation
Schöffski, P. et al. (2021). Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. European journal of cancer. pp. 12-23. [Online].